A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies

ID Number 16-1672

Principal Investigator(s)
Joshua Brody

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety, tolerability and effectiveness of an experimental drug called MK-3475 (pembrolizumab) and to evaluate disease response rate to MK-3475 (pembrolizumab).  An experimental drug is not approved by the UNited States FDA for use except in research studies. MK-3475 has been approved for use in certain types of adult melanoma and lung cancer however it has not been approved in any other cancers.

Contact Information
Dana Ostrowski
(212) 824-7309

Recruiting Patients: Yes